相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation
Ana Moreno et al.
AIDS (2008)
Raltegravir: an integrase inhibitor for HIV-1
Teresa H. Evering et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Viral hepatitis and HIV coinfection
Mark S. Sulkowski
JOURNAL OF HEPATOLOGY (2008)
Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays
Leo Heyndrickx et al.
JOURNAL OF VIROLOGICAL METHODS (2008)
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HIV-Infected liver and kidney transplant recipients: 1-and 3-year outcomes
M. E. Roland et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
Bruce L. Gilliam et al.
AIDS (2007)
Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
Thomas J. Ketas et al.
VIROLOGY (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
Alonso Heredia et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Use of sirolimus in solid organ transplantation
Joshua J. Augustine et al.
DRUGS (2007)
Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles
Paul D. Cornwell et al.
TOXICOLOGIC PATHOLOGY (2007)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
JM Strizki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density
S Willey et al.
ANTIVIRAL RESEARCH (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Combined effect of CCR5-Δ32 heterozygosity and the CCR5 promoter polymorphism-2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission
F Hladik et al.
JOURNAL OF VIROLOGY (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
SK Gupta et al.
CLINICAL INFECTIOUS DISEASES (2005)
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
EJ Platt et al.
JOURNAL OF VIROLOGY (2005)
Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients
MSA Kumar et al.
KIDNEY INTERNATIONAL (2005)
Enfuvirtide: the first HIV fusion inhibitor
A Lazzarin
EXPERT OPINION ON PHARMACOTHERAPY (2005)
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle
LG Abrahamyan et al.
JOURNAL OF VIROLOGY (2005)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy
J Reynes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1
A Heredia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication
J Roy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antiretroviral-drug resistance among patients recently infected with HIV
SJ Little et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Adherence to HAART among patients with HIV: breakthroughs and barriers
JR Ickovics et al.
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion
GB Melikyan et al.
JOURNAL OF CELL BIOLOGY (2000)
Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2000)
CD4(+) T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1
J Reynes et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
分享论文
